A Phase Ib/II Study of Olaparib With Sapacitabine in BRCA Mutant Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 07 Jan 2019
At a glance
- Drugs Olaparib (Primary) ; Sapacitabine (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Jan 2019 According to a Cyclacel Pharmaceuticals media release, initial data readout is expected in 2019.
- 01 Oct 2018 Status changed from not yet recruiting to recruiting.
- 20 Aug 2018 Status changed from planning to not yet recruiting.